All In Biotech

Investigational drug · Phase 3

Tirabrutinib

Also called: ONO-4059

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pemphigus, Steroid-resistant Pemphigus, Relapsed/Refractory Primary Central Nervous System Lymphoma.

Phase 3

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

16

Any phase or sponsor naming "Tirabrutinib"

First trial start

2021

Dec 29, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Tirabrutinib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Pemphigus
  • Steroid-resistant Pemphigus
  • Relapsed/Refractory Primary Central Nervous System Lymphoma
  • Refractory Primary Central Nervous System Lymphoma
  • Primary CNS Lymphoma

Approved drugs for the same conditions: Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Tirabrutinib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 142 on PubMed

Also in development for Pemphigus

  • B007Phase 33 trials

    Shanghai Jiaolian Drug Research and Development Co., Ltd · Pemphigus, Primary Membranous Nephropathy, Generalized Myasthenia Gravis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.